Earlier this year I wrote about the FDA's decision to approve a Geron Corporation embryonic stem cell trial in humans, for which I was interviewed by CBS2 News. (You can see the hopelessly biased story here.)
After the interview, off-camera, I remarked to the reporter that I hoped no spinal cord injury patients would end up getting hurt as a result of this trial, but given the tendency of embryonic stem cells to form tumors, I couldn't see much reason for optimism.
Now we find out that the trial is being "delayed". And, given Geron's history of snake oil salesmanship, the rapacious hucksters may never get their chance.
Meanwhile, advances in adult stem cell research continue apace.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment